Catalyst Pharmaceuticals, Inc. (CPRX) 의 후행 P/E는 14.4, 선행 P/E 14.2. 후행 이익수익률은 6.95%, 선행 이익수익률 7.06%. PEG 0.51 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $17.54.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 92/100 6/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | -4.8 | 0.40 | 2.21 | 0.00 | - |
| 2017 | -18.2 | 4.01 | 4.14 | 0.00 | - |
| 2018 | -5.8 | -0.10 | 3.88 | 394.11 | - |
| 2019 | 12.1 | -0.06 | 4.41 | 3.77 | - |
| 2020 | 4.6 | 0.03 | 2.04 | 2.90 | - |
| 2021 | 17.7 | -0.38 | 3.38 | 4.97 | - |
| 2022 | 23.1 | 0.21 | 6.40 | 8.98 | - |
| 2023 | 25.0 | -1.54 | 4.61 | 4.49 | - |
| 2024 | 15.1 | 0.14 | 3.40 | 5.03 | - |
| 2025 | 13.3 | 0.50 | 2.99 | 4.85 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $-0.22 | $0.00 | $-18.07M | - |
| 2017 | $-0.21 | $0.00 | $-18.41M | - |
| 2018 | $-0.33 | $500K | $-34M | -6800.7% |
| 2019 | $0.30 | $102.31M | $31.88M | 31.2% |
| 2020 | $0.71 | $119.07M | $74.98M | 63% |
| 2021 | $0.37 | $140.83M | $39.48M | 28% |
| 2022 | $0.75 | $214.2M | $83.08M | 38.8% |
| 2023 | $0.63 | $398.2M | $71.41M | 17.9% |
| 2024 | $1.31 | $491.73M | $163.89M | 33.3% |
| 2025 | $1.68 | $588.99M | $214.33M | 36.4% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $1.85 | $1.68 – $2.02 | $630.63M | $624.33M – $634.19M | 4 |
| 2027 | $2.15 | $1.91 – $2.35 | $696.91M | $678.23M – $711.71M | 4 |
| 2028 | $2.24 | $1.89 – $2.58 | $765.93M | $765.91M – $765.94M | 2 |
| 2029 | $2.50 | $2.38 – $2.57 | $843.73M | $812.4M – $862.3M | 1 |
| 2030 | $2.70 | $2.57 – $2.78 | $894.35M | $861.14M – $914.03M | 1 |
